Education
About Us
Working with TipRanks
Follow Us
Vericel Corporation (VCEL)
NASDAQ:VCEL
VCEL Stock Chart & Stats
$37.85
$1.36(2.35%)
At close: 4:00 PM EST
$37.85
$1.36(2.35%)
Day’s Range― - ―
52-Week Range$29.24 - $63.00
Previous CloseN/A
Volume83.17K
Average Volume (3M)515.27K
Market Cap
$1.91B
Enterprise Value$1.90B
Total Cash (Recent Filing)$135.38M
Total Debt (Recent Filing)$98.01M
Price to Earnings (P/E)156.6
Beta0.98
Next Earnings
Feb 26, 2026EPS Estimate
0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.10
Shares Outstanding50,574,024
10 Day Avg. Volume455,017
30 Day Avg. Volume515,274
Financial Highlights & Ratios
PEG Ratio-0.63
Price to Book (P/B)9.19
Price to Sales (P/S)11.31
P/FCF Ratio-461.58
Enterprise Value/Market Cap1.00
Enterprise Value/Revenue7.36
Enterprise Value/Gross Profit9.97
Enterprise Value/Ebitda80.06
Forecast
1Y Price Target
$57.67Price Target Upside52.36% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)0.57
Revenue Forecast (FY)$324.95M
Bulls Say, Bears Say
Bulls Say
MACI Commercial MomentumRecord MACI implants and growing surgeon adoption indicate accelerating commercial traction that should boost procedure volumes and support revenue growth.
Product Expansion And PipelineTransitioning commercial manufacturing to a new facility and pursuing international MACI expansion plus a potential ankle indication create multiple avenues for longer-term market growth.
Profitability And Cash PositionRenewed net income profitability, improving cash flow and a debt-free balance sheet increase financial stability and reduce financing risk while margins remain strong.
Bears Say
Burn Care Commercial WeaknessDeclining burn care revenue and persistent commercial challenges in that franchise could limit overall revenue growth and complicate cross-selling plans.
Burn Care VolatilitySequential decline in burn care revenue despite annual improvement highlights volatility that could pressure guidance and investor confidence.
Government Procurement RiskA government shutdown pause on the BARDA request for proposals delays a potential Nexobrid contract opportunity and introduces uncertainty around related revenue upside.
Vericel News
VCEL FAQ
What was Vericel Corporation’s price range in the past 12 months?
Vericel Corporation lowest stock price was $29.24 and its highest was $63.00 in the past 12 months.
What is Vericel Corporation’s market cap?
Vericel Corporation’s market cap is $1.91B.
When is Vericel Corporation’s upcoming earnings report date?
Vericel Corporation’s upcoming earnings report date is Feb 26, 2026 which is in 29 days.
How were Vericel Corporation’s earnings last quarter?
Vericel Corporation released its earnings results on Nov 06, 2025. The company reported $0.1 earnings per share for the quarter, beating the consensus estimate of -$0.006 by $0.106.
Is Vericel Corporation overvalued?
According to Wall Street analysts Vericel Corporation’s price is currently Undervalued.
Does Vericel Corporation pay dividends?
Vericel Corporation does not currently pay dividends.
What is Vericel Corporation’s EPS estimate?
Vericel Corporation’s EPS estimate is 0.39.
How many shares outstanding does Vericel Corporation have?
Vericel Corporation has 50,574,024 shares outstanding.
What happened to Vericel Corporation’s price movement after its last earnings report?
Vericel Corporation reported an EPS of $0.1 in its last earnings report, beating expectations of -$0.006. Following the earnings report the stock price went up 4.167%.
Which hedge fund is a major shareholder of Vericel Corporation?
Currently, no hedge funds are holding shares in VCEL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Vericel Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$57.67 (52.36% Upside)
$57.67 (52.36% Upside)
Blogger Sentiment
Neutral
VCEL Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 272.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $189.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 2.4%
Last 30 Days ▲ 2.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-34.35%
12-Months-Change
Fundamentals
Return on Equity
4.52%
Trailing 12-Months
Asset Growth
16.10%
Trailing 12-Months
Company Description
Vericel Corporation
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product is NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
VCEL Company Deck
VCEL Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted Vericel's strong financial performance with record revenue and profit growth, driven by the success of MACI and the launch of MACI Arthro. However, there are potential challenges related to government processes and reimbursement policies that could impact future growth.View all VCEL earnings summariesVCEL Stock 12 Month Forecast
Average Price Target
$57.67
▲(52.36% Upside)
Technical Analysis
Ownership Overview
Currently, No data available
---